Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5′-DFUR in breast cancer MCF7 cells

Biochemical Pharmacology

Volumn 72, Issue 12, 2006, Pages 1646-1656

  Molina Arcas, Míriam ^a   Moreno Bueno, Gema ^b   Cano Soldado, Pedro ^a   Hernández Vargas, Héctor ^b   Casado, F Javier ^a   Palacios, José ^b   Pastor Anglada, Marçal ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

5 DFUR; Breast cancer; cDNA microarray; hENT1; Nucleoside transporter

Indexed keywords

CAPECITABINE; CARRIER PROTEIN; DOXIFLURIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; NUCLEOTIDE TRANSPORTER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE PROGRESSION; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG UPTAKE; GENE TARGETING; HUMAN; HUMAN CELL; MEMBRANE TRANSPORT; METABOLITE; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSCRIPTOMICS;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; FLOXURIDINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BIOSYNTHESIS; TRANSCRIPTION, GENETIC;

EID: 33751085679     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.07.036     Document Type: Article

References (38)

1. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3 (2003) 330-338
2. Baldwin S.A., Beal P.R., Yao S.Y., King A.E., Cass C.E., and Young J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447 (2004) 735-743
3. Gray J.H., Owen R.P., and Giacomini K.M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447 (2004) 728-734
4. Pastor-Anglada M., Molina-Arcas M., Casado F.J., Bellosillo B., Colomer D., and Gil J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 18 (2004) 385-393
5. Mata J.F., Garcia-Manteiga J.M., Lostao M.P., Fernandez-Veledo S., Guillen-Gomez E., Larrayoz I.M., et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 59 (2001) 1542-1548
6. Pastor-Anglada M., Casado F.J., Valdes R., Mata J., Garcia-Manteiga J., and Molina M. Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Mol Membr Biol 18 (2001) 81-85
7. Mackey J.R., Jennings L.L., Clarke M.L., Santos C.L., Dabbagh L., Vsianska M., et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 8 (2002) 110-116
8. Molina-Arcas M., Bellosillo B., Casado F.J., Montserrat E., Gil J., Colomer D., et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 101 (2003) 2328-2334
9. Molina-Arcas M., Marce S., Villamor N., Huber-Ruano I., Casado F.J., Bellosillo B., et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 19 (2005) 64-68
10. Spratlin J., Sangha R., Glubrecht D., Dabbagh L., Young J.D., Dumontet C., et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10 (2004) 6956-6961
11. Fernandez-Veledo S., Valdes R., Wallenius V., Casado F.J., and Pastor-Anglada M. Up-regulation of the high-affinity pyrimidine-preferring nucleoside transporter concentrative nucleoside transporter 1 by tumor necrosis factor-alpha and interleukin-6 in liver parenchymal cells. J Hepatol 41 (2004) 538-544
12. Tracey L., Villuendas R., Ortiz P., Dopazo A., Spiteri I., Lombardia L., et al. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol 161 (2002) 1825-1837
13. Vaquerizas J.M., Dopazo J., and Diaz-Uriarte R. DNMAD: web-based diagnosis and normalization for microarray data. Bioinformatics 20 (2004) 3656-3658
14. Herrero J., Diaz-Uriarte R., and Dopazo J. Gene expression data preprocessing. Bioinformatics 19 (2003) 655-656
15. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
16. Farre X., Guillen-Gomez E., Sanchez L., Hardisson D., Plaza Y., Lloberas J., et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 112 (2004) 959-966
17. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58 (1998) 4349-4357
18. Gati W.P., Paterson A.R., Belch A.R., Chlumecky V., Larratt L.M., Mant M.J., et al. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk Lymphoma 32 (1998) 45-54
19. Backus H.H., Pinedo H.M., Wouters D., Kuiper C.M., Jansen G., van Groeningen C.J., et al. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol Res 12 (2000) 231-239
20. Troester M.A., Hoadley K.A., Sorlie T., Herbert B.S., Borresen-Dale A.L., Lonning P.E., et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64 (2004) 4218-4226
21. Park J.S., Young Yoon S., Kim J.M., Yeom Y.I., Kim Y.S., and Kim N.S. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 214 (2004) 19-33
22. Reigner B., Watanabe T., Schuller J., Lucraft H., Sasaki Y., Bridgewater J., et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 52 (2003) 193-201
23. Rosenwald A., Chuang E.Y., Davis R.E., Wiestner A., Alizadeh A.A., Arthur D.C., et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104 (2004) 1428-1434
24. Liu G., and Chen X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 21 (2002) 7195-7204
25. Okamura S., Arakawa H., Tanaka T., Nakanishi H., Ng C.C., Taya Y., et al. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 8 (2001) 85-94
26. Zhao R., Gish K., Murphy M., Yin Y., Notterman D., Hoffman W.H., et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14 (2000) 981-993
27. Kho P.S., Wang Z., Zhuang L., Li Y., Chew J.L., Ng H.H., et al. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 279 (2004) 21183-21192
28. Hernandez-Vargas H., Ballestar E., Carmona-Saez P., von Kobbe C., Banon-Rodriguez I., Esteller M., et al. Transcriptional profiling of MCF7 breast cancer cells in response to 5-fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 119 (2006) 1164-1175
29. Zheng X., and Chen X. Aquaporin 3, a glycerol and water transporter, is regulated by p73 of the p53 family. FEBS Lett 489 (2001) 4-7
30. Gasch A.P., Spellman P.T., Kao C.M., Carmel-Harel O., Eisen M.B., Storz G., et al. Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell 11 (2000) 4241-4257
31. Kanamaru R., Kakuta H., Sato T., Ishioka C., and Wakui A. The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol 17 (1986) 43-46
32. Goh L.B., Mack P., and Lee C.W. Nitrobenzylthioinosine-binding protein overexpression in human breast, liver, stomach and colorectal tumour tissues. Anticancer Res 15 (1995) 2575-2579
33. Pressacco J., Wiley J.S., Jamieson G.P., Erlichman C., and Hedley D.W. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer 72 (1995) 939-942
34. Wiley J.S., Cebon J.S., Jamieson G.P., Szer J., Gibson J., Woodruff R.K., et al. Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter. Leukemia 8 (1994) 181-185
35. Reiman T., Clarke M.L., Dabbagh L., Vsianska M., Coupland R.W., Belch A.R., et al. Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease. Leuk Lymphoma 43 (2002) 1435-1440
36. Stam R.W., den Boer M.L., Meijerink J.P., Ebus M.E., Peters G.J., Noordhuis P., et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101 (2003) 1270-1276
37. Galmarini C.M., Thomas X., Calvo F., Rousselot P., Rabilloud M., El Jaffari A., et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117 (2002) 860-868
38. Marce S., Molina-Arcas M., Villamor N., Casado F.J., Campo E., Pastor-Anglada M., et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91 (2006) 895-902